{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:41:58Z","timestamp":1787308918091,"version":"build-2736575974"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2018\/30\/A\/NZ3\/00412"],"award-info":[{"award-number":["2018\/30\/A\/NZ3\/00412"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2021\/40\/Q\/NZ3\/00165"],"award-info":[{"award-number":["2021\/40\/Q\/NZ3\/00165"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2024\/52\/L\/NZ3\/00142"],"award-info":[{"award-number":["2024\/52\/L\/NZ3\/00142"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/35\/B\/NZ3\/02817"],"award-info":[{"award-number":["2019\/35\/B\/NZ3\/02817"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Despite extensive studies, Duchenne muscular dystrophy, a neuromuscular disorder caused by the lack of dystrophin, a key muscle structural protein, remains an incurable disease. One of the potential treatment options currently being investigated is cell therapy, although it has not yet been clinically established. Several strategies, including muscle satellite cells, mesoangioblasts (vessel-associated multipotent stem cells), and induced pluripotent stem cell (iPSC)-derived muscle cells, have emerged as tools for restoring dystrophin expression and regenerating damaged muscle tissue. Nevertheless, each of these approaches faces significant limitations, including poor cell engraftment, low delivery efficiency, and the risk of immune rejection. Furthermore, long-term safety, the possibility of tumorigenicity, and off-target effects must be rigorously evaluated. Importantly, the latter technology, utilizing cardiomyocytes differentiated from iPSC, holds the potential for addressing cardiomyopathy, the major cause of death of DMD patients. At the same time, several interventions using cells with claimed stem cell potential have emerged, raising both scientific and ethical concerns. This review summarizes recent advancements in the development of cell therapies for DMD, highlighting promising progress while critically analysing questionable approaches.<\/jats:p>","DOI":"10.1007\/s00018-025-05904-5","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T04:17:30Z","timestamp":1760156250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cell therapy for Duchenne muscular dystrophy: promises, challenges, and controversies"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3523-3560","authenticated-orcid":false,"given":"Agnieszka","family":"\u0141oboda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5687-0839","authenticated-orcid":false,"given":"J\u00f3zef","family":"Dulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"5904_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S et al (2015) The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36:395\u2013402. https:\/\/doi.org\/10.1002\/humu.22758","journal-title":"Hum Mutat"},{"key":"5904_CR2","doi-asserted-by":"publisher","first-page":"12140","DOI":"10.1021\/acsnano.8b05721","volume":"12","author":"S Le","year":"2018","unstructured":"Le S, Yu M, Hovan L et al (2018) Dystrophin as a molecular shock absorber. ACS Nano 12:12140\u201312148. https:\/\/doi.org\/10.1021\/acsnano.8b05721","journal-title":"ACS Nano"},{"key":"5904_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1113\/jphysiol.2010.201921","volume":"589","author":"KS Ramaswamy","year":"2011","unstructured":"Ramaswamy KS, Palmer ML, van der Meulen JH et al (2011) Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J Physiol 589:1195\u20131208. https:\/\/doi.org\/10.1113\/jphysiol.2010.201921","journal-title":"J Physiol"},{"key":"5904_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","volume":"96","author":"DG Allen","year":"2016","unstructured":"Allen DG, Whitehead NP, Froehner SC (2016) Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev 96:253\u2013305. https:\/\/doi.org\/10.1152\/physrev.00007.2015","journal-title":"Physiol Rev"},{"key":"5904_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bbamem.2013.08.023","volume":"1838","author":"B Constantin","year":"2014","unstructured":"Constantin B (2014) Dystrophin complex functions as a scaffold for signalling proteins. Biochimica et Biophysica Acta (BBA) 1838:635\u2013642. https:\/\/doi.org\/10.1016\/j.bbamem.2013.08.023","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"5904_CR6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/01.cir.103.6.864","volume":"103","author":"L Loufrani","year":"2001","unstructured":"Loufrani L, Matrougui K, Gorny D et al (2001) Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation 103:864\u2013870. https:\/\/doi.org\/10.1161\/01.cir.103.6.864","journal-title":"Circulation"},{"key":"5904_CR7","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1161\/ATVBAHA.112.301172","volume":"33","author":"M Palladino","year":"2013","unstructured":"Palladino M, Gatto I, Neri V et al (2013) Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy. Arterioscler Thromb Vasc Biol 33:2867\u20132876. https:\/\/doi.org\/10.1161\/ATVBAHA.112.301172","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5904_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1161\/01.ATV.0000118683.99628.42","volume":"24","author":"L Loufrani","year":"2004","unstructured":"Loufrani L, Dubroca C, You D et al (2004) Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: total recovery after a treatment with the aminoglycoside gentamicin. Arterioscler Thromb Vasc Biol 24:671\u2013676. https:\/\/doi.org\/10.1161\/01.ATV.0000118683.99628.42","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5904_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1006\/bbrc.1993.1382","volume":"192","author":"JP Hugnot","year":"1993","unstructured":"Hugnot JP, Gilgenkrantz H, Chafey P et al (1993) Expression of the dystrophin gene in cultured fibroblasts. Biochem Biophys Res Commun 192:69\u201374. https:\/\/doi.org\/10.1006\/bbrc.1993.1382","journal-title":"Biochem Biophys Res Commun"},{"key":"5904_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ng.2974","volume":"46","author":"Y Wang","year":"2014","unstructured":"Wang Y, Marino-Enriquez A, Bennett RR et al (2014) Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet 46:601. https:\/\/doi.org\/10.1038\/ng.2974","journal-title":"Nat Genet"},{"key":"5904_CR11","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","volume":"72","author":"A \u0141oboda","year":"2020","unstructured":"\u0141oboda A, Dulak J (2020) Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. Pharmacol Rep 72:1227\u20131263. https:\/\/doi.org\/10.1007\/s43440-020-00134-x","journal-title":"Pharmacol Rep"},{"key":"5904_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6","journal-title":"Lancet Neurol"},{"key":"5904_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1183\/09031936.06.00059906","volume":"28","author":"F Lofaso","year":"2006","unstructured":"Lofaso F, Orlikowski D, Raphael J-C (2006) Ventilatory assistance in patients with Duchenne muscular dystrophy. Eur Respir J 28:468\u2013469. https:\/\/doi.org\/10.1183\/09031936.06.00059906","journal-title":"Eur Respir J"},{"key":"5904_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1017\/s0012162201002778","volume":"44","author":"DGM McDonald","year":"2002","unstructured":"McDonald DGM, Kinali M, Gallagher AC et al (2002) Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 44:695\u2013698. https:\/\/doi.org\/10.1017\/s0012162201002778","journal-title":"Dev Med Child Neurol"},{"key":"5904_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jama.1996.03530410049032","volume":"275","author":"L Politano","year":"1996","unstructured":"Politano L, Nigro V, Nigro G et al (1996) Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA 275:1335\u20131338","journal-title":"JAMA"},{"key":"5904_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3349\/ymj.2011.52.1.192","volume":"52","author":"T-J Song","year":"2011","unstructured":"Song T-J, Lee K-A, Kang S-W et al (2011) Three cases of manifesting female carriers in patients with Duchenne muscular dystrophy. Yonsei Med J 52:192\u2013195. https:\/\/doi.org\/10.3349\/ymj.2011.52.1.192","journal-title":"Yonsei Med J"},{"key":"5904_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.nmd.2018.04.005","volume":"28","author":"M Ishizaki","year":"2018","unstructured":"Ishizaki M, Kobayashi M, Adachi K et al (2018) Female dystrophinopathy: review of current literature. Neuromuscul Disord 28:572\u2013581. https:\/\/doi.org\/10.1016\/j.nmd.2018.04.005","journal-title":"Neuromuscul Disord"},{"key":"5904_CR18","doi-asserted-by":"publisher","first-page":"707838","DOI":"10.3389\/fneur.2021.707838","volume":"12","author":"T\u00c5 Solheim","year":"2021","unstructured":"Solheim T\u00c5, Fornander F, Raja AA et al (2021) Cardiac involvement in women with pathogenic dystrophin gene variants. Front Neurol 12:707838. https:\/\/doi.org\/10.3389\/fneur.2021.707838","journal-title":"Front Neurol"},{"key":"5904_CR19","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1136\/heartjnl-2017-311269","volume":"103","author":"D D\u2019Amario","year":"2017","unstructured":"D\u2019Amario D, Amodeo A, Adorisio R et al (2017) A current approach to heart failure in Duchenne muscular dystrophy. Heart 103:1770\u20131779. https:\/\/doi.org\/10.1136\/heartjnl-2017-311269","journal-title":"Heart"},{"key":"5904_CR20","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1161\/CIRCRESAHA.116.308402","volume":"118","author":"JA Rafael-Fortney","year":"2016","unstructured":"Rafael-Fortney JA, Chadwick JA, Raman SV (2016) Duchenne muscular dystrophy mice and men: can understanding a genetic cardiomyopathy inform treatment of other myocardial diseases?? Circ Res 118:1059\u20131061. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308402","journal-title":"Circ Res"},{"key":"5904_CR21","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","volume":"131","author":"EM McNally","year":"2015","unstructured":"McNally EM, Kaltman JR, Benson DW et al (2015) Contemporary cardiac issues in Duchenne muscular dystrophy. Working group of the National heart, lung, and blood Institute in collaboration with parent project muscular dystrophy. Circulation 131:1590\u20131598. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.015151","journal-title":"Circulation"},{"key":"5904_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17:251\u2013267. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3","journal-title":"Lancet Neurol"},{"key":"5904_CR23","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.1007\/s00018-021-03862-2","volume":"78","author":"U Florczyk-Soluch","year":"2021","unstructured":"Florczyk-Soluch U, Polak K, Dulak J (2021) The multifaceted view of heart problem in Duchenne muscular dystrophy. Cell Mol Life Sci 78:5447\u20135468. https:\/\/doi.org\/10.1007\/s00018-021-03862-2","journal-title":"Cell Mol Life Sci"},{"key":"5904_CR24","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J, Hill M, Guglieri M et al (2021) Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology 97:e2304\u2013e2314. https:\/\/doi.org\/10.1212\/WNL.0000000000012910","journal-title":"Neurology"},{"key":"5904_CR25","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jpeds.2014.07.006","volume":"165","author":"KT Mirski","year":"2014","unstructured":"Mirski KT, Crawford TO (2014) Motor and cognitive delay in Duchenne muscular dystrophy: implication for early diagnosis. J Pediatr 165:1008\u20131010. https:\/\/doi.org\/10.1016\/j.jpeds.2014.07.006","journal-title":"J Pediatr"},{"key":"5904_CR26","doi-asserted-by":"publisher","first-page":"16474","DOI":"10.1073\/pnas.1307680110","volume":"110","author":"J von Maltzahn","year":"2013","unstructured":"von Maltzahn J, Jones AE, Parks RJ, Rudnicki MA (2013) Pax7 is critical for the normal function of satellite cells in adult skeletal muscle. Proc Natl Acad Sci U S A 110:16474\u201316479. https:\/\/doi.org\/10.1073\/pnas.1307680110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5904_CR27","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/nm.3990","volume":"21","author":"NA Dumont","year":"2015","unstructured":"Dumont NA, Wang YX, von Maltzahn J et al (2015) Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med 21:1455\u20131463. https:\/\/doi.org\/10.1038\/nm.3990","journal-title":"Nat Med"},{"key":"5904_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00441-010-0976-6","volume":"340","author":"M Kottlors","year":"2010","unstructured":"Kottlors M, Kirschner J (2010) Elevated satellite cell number in Duchenne muscular dystrophy. Cell Tissue Res 340:541\u2013548. https:\/\/doi.org\/10.1007\/s00441-010-0976-6","journal-title":"Cell Tissue Res"},{"key":"5904_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.molmed.2016.04.002","volume":"22","author":"NC Chang","year":"2016","unstructured":"Chang NC, Chevalier FP, Rudnicki MA (2016) Satellite cells in muscular dystrophy - lost in polarity. Trends Mol Med 22:479\u2013496. https:\/\/doi.org\/10.1016\/j.molmed.2016.04.002","journal-title":"Trends Mol Med"},{"key":"5904_CR30","doi-asserted-by":"publisher","first-page":"e13682","DOI":"10.1002\/jcsm.13682","volume":"16","author":"ME Esper","year":"2025","unstructured":"Esper ME, Brun CE, Lin AYT et al (2025) Intrinsic muscle stem cell dysfunction contributes to impaired regeneration in the Mdx mouse. J Cachexia Sarcopenia Muscle 16:e13682. https:\/\/doi.org\/10.1002\/jcsm.13682","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"5904_CR31","doi-asserted-by":"publisher","first-page":"11842","DOI":"10.1038\/s41598-019-48156-7","volume":"9","author":"AF Ribeiro","year":"2019","unstructured":"Ribeiro AF, Souza LS, Almeida CF et al (2019) Muscle satellite cells and impaired late stage regeneration in different murine models for muscular dystrophies. Sci Rep 9:11842. https:\/\/doi.org\/10.1038\/s41598-019-48156-7","journal-title":"Sci Rep"},{"key":"5904_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41419-025-07755-1","volume":"16","author":"JA Granet","year":"2025","unstructured":"Granet JA, Robertson R, Cusmano AA et al (2025) Muscle stem cells in Duchenne muscular dystrophy exhibit molecular impairments and altered cell fate trajectories impacting regenerative capacity. Cell Death Dis 16:437. https:\/\/doi.org\/10.1038\/s41419-025-07755-1","journal-title":"Cell Death Dis"},{"key":"5904_CR33","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.2353\/ajpath.2010.090887","volume":"176","author":"S Fukada","year":"2010","unstructured":"Fukada S, Morikawa D, Yamamoto Y et al (2010) Genetic background affects properties of satellite cells and Mdx phenotypes. Am J Pathol 176:2414\u20132424. https:\/\/doi.org\/10.2353\/ajpath.2010.090887","journal-title":"Am J Pathol"},{"key":"5904_CR34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cell.2010.11.039","volume":"143","author":"A Sacco","year":"2010","unstructured":"Sacco A, Mourkioti F, Tran R et al (2010) Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx\/mtr mice. Cell 143:1059\u20131071. https:\/\/doi.org\/10.1016\/j.cell.2010.11.039","journal-title":"Cell"},{"key":"5904_CR35","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1073\/pnas.80.15.4856","volume":"80","author":"HM Blau","year":"1983","unstructured":"Blau HM, Webster C, Pavlath GK (1983) Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 80:4856\u20134860","journal-title":"Proc Natl Acad Sci USA"},{"key":"5904_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13395-019-0207-0","volume":"9","author":"I Bronisz-Budzy\u0144ska","year":"2019","unstructured":"Bronisz-Budzy\u0144ska I, Chwalenia K, Mucha O et al (2019) Mir-146a deficiency does not aggravate muscular dystrophy in Mdx mice. Skelet Muscle 9:22. https:\/\/doi.org\/10.1186\/s13395-019-0207-0","journal-title":"Skelet Muscle"},{"key":"5904_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13395-020-00255-0","volume":"10","author":"I Bronisz-Budzy\u0144ska","year":"2020","unstructured":"Bronisz-Budzy\u0144ska I, Kozakowska M, Podkalicka P et al (2020) The role of Nrf2 in acute and chronic muscle injury. Skelet Muscle 10:35. https:\/\/doi.org\/10.1186\/s13395-020-00255-0","journal-title":"Skelet Muscle"},{"key":"5904_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13395-021-00276-3","volume":"11","author":"O Mucha","year":"2021","unstructured":"Mucha O, Podkalicka P, Kazir\u00f3d K et al (2021) Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy. Skelet Muscle 11:21. https:\/\/doi.org\/10.1186\/s13395-021-00276-3","journal-title":"Skelet Muscle"},{"key":"5904_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1089\/ars.2017.7435","volume":"29","author":"K Pietraszek-Gremplewicz","year":"2018","unstructured":"Pietraszek-Gremplewicz K, Kozakowska M, Bronisz-Budzynska I et al (2018) Heme oxygenase-1 influences satellite cells and progression of Duchenne muscular dystrophy in mice. Antioxid Redox Signal 29:128\u2013148. https:\/\/doi.org\/10.1089\/ars.2017.7435","journal-title":"Antioxid Redox Signal"},{"key":"5904_CR40","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/nbt.3297","volume":"33","author":"J Chal","year":"2015","unstructured":"Chal J, Oginuma M, Al Tanoury Z et al (2015) Differentiation of pluripotent stem cells to muscle fiber to model Duchenne muscular dystrophy. Nat Biotechnol 33:962\u2013969. https:\/\/doi.org\/10.1038\/nbt.3297","journal-title":"Nat Biotechnol"},{"key":"5904_CR41","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3389\/fphys.2020.00690","volume":"11","author":"TM Moore","year":"2020","unstructured":"Moore TM, Lin AJ, Strumwasser AR et al (2020) Mitochondrial dysfunction is an early consequence of partial or complete dystrophin loss in Mdx mice. Front Physiol 11:690. https:\/\/doi.org\/10.3389\/fphys.2020.00690","journal-title":"Front Physiol"},{"key":"5904_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/cvr\/cvad182","volume":"120","author":"K Andrysiak","year":"2024","unstructured":"Andrysiak K, Machaj G, Priesmann D et al (2024) Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment. Cardiovasc Res 120:69\u201381. https:\/\/doi.org\/10.1093\/cvr\/cvad182","journal-title":"Cardiovasc Res"},{"key":"5904_CR43","doi-asserted-by":"crossref","unstructured":"Mohiuddin M, Choi JJ, Lee NH et al (2020) Transplantation of Muscle Stem Cell Mitochondria Rejuvenates the Bioenergetic Function of Dystrophic Muscle. 2020.04.17.017822","DOI":"10.1101\/2020.04.17.017822"},{"key":"5904_CR44","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/stem.3094","volume":"37","author":"PR Matre","year":"2019","unstructured":"Matre PR, Mu X, Wu J et al (2019) CRISPR\/Cas9-based dystrophin restoration reveals a novel role for dystrophin in bioenergetics and stress resistance of muscle progenitors. Stem Cells 37:1615\u20131628. https:\/\/doi.org\/10.1002\/stem.3094","journal-title":"Stem Cells"},{"key":"5904_CR45","doi-asserted-by":"publisher","first-page":"16385","DOI":"10.1038\/s41598-020-73315-6","volume":"10","author":"H Sugihara","year":"2020","unstructured":"Sugihara H, Teramoto N, Nakamura K et al (2020) Cellular senescence-mediated exacerbation of Duchenne muscular dystrophy. Sci Rep 10:16385. https:\/\/doi.org\/10.1038\/s41598-020-73315-6","journal-title":"Sci Rep"},{"key":"5904_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s40478-023-01657-z","volume":"11","author":"N Cardone","year":"2023","unstructured":"Cardone N, Taglietti V, Baratto S et al (2023) Myopathologic trajectory in Duchenne muscular dystrophy (DMD) reveals lack of regeneration due to senescence in satellite cells. Acta Neuropathol Commun 11:167. https:\/\/doi.org\/10.1186\/s40478-023-01657-z","journal-title":"Acta Neuropathol Commun"},{"key":"5904_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008411","volume":"6","author":"S Biressi","year":"2014","unstructured":"Biressi S, Miyabara EH, Gopinath SD et al (2014) A wnt-TGF\u03b22 axis induces a fibrogenic program in muscle stem cells from dystrophic mice. Sci Transl Med 6:267ra176. https:\/\/doi.org\/10.1126\/scitranslmed.3008411","journal-title":"Sci Transl Med"},{"key":"5904_CR48","doi-asserted-by":"publisher","first-page":"1180980","DOI":"10.3389\/fphys.2023.1180980","volume":"14","author":"K Kodippili","year":"2023","unstructured":"Kodippili K, Rudnicki MA (2023) Satellite cell contribution to disease pathology in Duchenne muscular dystrophy. Front Physiol 14:1180980. https:\/\/doi.org\/10.3389\/fphys.2023.1180980","journal-title":"Front Physiol"},{"key":"5904_CR49","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1159\/000514305","volume":"211","author":"RL Filippelli","year":"2022","unstructured":"Filippelli RL, Chang NC (2022) Empowering muscle stem cells for the treatment of Duchenne muscular dystrophy. Cells Tissues Organs 211:641\u2013654. https:\/\/doi.org\/10.1159\/000514305","journal-title":"Cells Tissues Organs"},{"key":"5904_CR50","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00415-006-0212-1","volume":"253","author":"S Pradhan","year":"2006","unstructured":"Pradhan S, Ghosh D, Srivastava NK et al (2006) Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 253:1309\u20131316. https:\/\/doi.org\/10.1007\/s00415-006-0212-1","journal-title":"J Neurol"},{"key":"5904_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mus.23808","volume":"48","author":"EK Henricson","year":"2013","unstructured":"Henricson EK, Abresch RT, Cnaan A et al (2013) The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 48:55\u201367. https:\/\/doi.org\/10.1002\/mus.23808","journal-title":"Muscle Nerve"},{"key":"5904_CR52","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","volume":"89","author":"RG Victor","year":"2017","unstructured":"Victor RG, Sweeney HL, Finkel R et al (2017) A phase 3 randomized placebo-controlled trial of Tadalafil for Duchenne muscular dystrophy. Neurology 89:1811\u20131820. https:\/\/doi.org\/10.1212\/WNL.0000000000004570","journal-title":"Neurology"},{"key":"5904_CR53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","volume":"34","author":"S Guiraud","year":"2017","unstructured":"Guiraud S, Davies KE (2017) Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr Opin Pharmacol 34:36\u201348. https:\/\/doi.org\/10.1016\/j.coph.2017.04.002","journal-title":"Curr Opin Pharmacol"},{"key":"5904_CR54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","volume":"16","author":"S Kourakis","year":"2021","unstructured":"Kourakis S, Timpani CA, Campelj DG et al (2021) Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better? Orphanet J Rare Dis 16:117. https:\/\/doi.org\/10.1186\/s13023-021-01758-9","journal-title":"Orphanet J Rare Dis"},{"key":"5904_CR55","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","volume":"77","author":"DM Escolar","year":"2011","unstructured":"Escolar DM, Hache LP, Clemens PR et al (2011) Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77:444\u2013452. https:\/\/doi.org\/10.1212\/WNL.0b013e318227b164","journal-title":"Neurology"},{"key":"5904_CR56","doi-asserted-by":"publisher","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","volume":"5","author":"JK Mah","year":"2022","unstructured":"Mah JK, Clemens PR, Guglieri M et al (2022) Efficacy and safety of Vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open 5:e2144178. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44178","journal-title":"JAMA Netw Open"},{"key":"5904_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175928","volume":"955","author":"M Myszka","year":"2023","unstructured":"Myszka M, Mucha O, Podkalicka P et al (2023) Sodium hydrosulfide moderately alleviates the hallmark symptoms of Duchenne muscular dystrophy in Mdx mice. Eur J Pharmacol 175928. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175928","journal-title":"Eur J Pharmacol"},{"key":"5904_CR58","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/biom13111648","volume":"13","author":"O Mucha","year":"2023","unstructured":"Mucha O, Myszka M, Podkalicka P et al (2023) Proteome profiling of the dystrophic Mdx mice diaphragm. Biomolecules 13:1648. https:\/\/doi.org\/10.3390\/biom13111648","journal-title":"Biomolecules"},{"key":"5904_CR59","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s00018-022-04636-0","volume":"79","author":"K Kazir\u00f3d","year":"2022","unstructured":"Kazir\u00f3d K, Myszka M, Dulak J, \u0141oboda A (2022) Hydrogen sulfide as a therapeutic option for the treatment of Duchenne muscular dystrophy and other muscle-related diseases. Cell Mol Life Sci 79:608. https:\/\/doi.org\/10.1007\/s00018-022-04636-0","journal-title":"Cell Mol Life Sci"},{"key":"5904_CR60","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/cells13020158","volume":"13","author":"A \u0141oboda","year":"2024","unstructured":"\u0141oboda A, Dulak J (2024) Cardioprotective effects of hydrogen sulfide and its potential therapeutic implications in the amelioration of Duchenne muscular dystrophy cardiomyopathy. Cells 13:158. https:\/\/doi.org\/10.3390\/cells13020158","journal-title":"Cells"},{"key":"5904_CR61","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2024.0702","author":"M Myszka","year":"2025","unstructured":"Myszka M, Jakubczak E, Mucha O et al (2025) GYY4137, a slow-releasing hydrogen sulfide donor, attenuates skeletal muscle abnormalities in a murine model of Duchenne muscular dystrophy. Antioxid Redox Signal. https:\/\/doi.org\/10.1089\/ars.2024.0702","journal-title":"Antioxid Redox Signal"},{"key":"5904_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1750-3639.1996.tb00781.x","volume":"6","author":"DJ Blake","year":"1996","unstructured":"Blake DJ, Tinsley JM, Davies KE (1996) Utrophin: a structural and functional comparison to dystrophin. Brain Pathol 6:37\u201347. https:\/\/doi.org\/10.1111\/j.1750-3639.1996.tb00781.x","journal-title":"Brain Pathol"},{"key":"5904_CR63","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/bf02388063","volume":"25","author":"A Clerk","year":"1993","unstructured":"Clerk A, Morris GE, Dubowitz V et al (1993) Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. Histochem J 25:554\u2013561. https:\/\/doi.org\/10.1007\/bf02388063","journal-title":"Histochem J"},{"key":"5904_CR64","doi-asserted-by":"publisher","first-page":"E837","DOI":"10.3390\/genes11080837","volume":"11","author":"C Sun","year":"2020","unstructured":"Sun C, Shen L, Zhang Z, Xie X (2020) Therapeutic strategies for Duchenne muscular dystrophy: an update. Genes (Basel) 11:E837. https:\/\/doi.org\/10.3390\/genes11080837","journal-title":"Genes (Basel)"},{"key":"5904_CR65","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.nmd.2021.08.004","volume":"31","author":"F Fortunato","year":"2021","unstructured":"Fortunato F, Farn\u00e8 M, Ferlini A (2021) The DMD gene and therapeutic approaches to restore dystrophin. Neuromuscul Disord 31:1013\u20131020. https:\/\/doi.org\/10.1016\/j.nmd.2021.08.004","journal-title":"Neuromuscul Disord"},{"key":"5904_CR66","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","volume":"50","author":"M Koenig","year":"1987","unstructured":"Koenig M, Hoffman EP, Bertelson CJ et al (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509\u2013517. https:\/\/doi.org\/10.1016\/0092-8674(87)90504-6","journal-title":"Cell"},{"key":"5904_CR67","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/349334a0","volume":"349","author":"CC Lee","year":"1991","unstructured":"Lee CC, Pearlman JA, Chamberlain JS, Caskey CT (1991) Expression of recombinant dystrophin and its localization to the cell membrane. Nature 349:334\u2013336. https:\/\/doi.org\/10.1038\/349334a0","journal-title":"Nature"},{"key":"5904_CR68","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1085","volume":"10","author":"P Gregorevic","year":"2004","unstructured":"Gregorevic P, Blankinship MJ, Allen JM et al (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10:828\u2013834. https:\/\/doi.org\/10.1038\/nm1085","journal-title":"Nat Med"},{"key":"5904_CR69","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","volume":"632","author":"H Tasfaout","year":"2024","unstructured":"Tasfaout H, Halbert CL, McMillen TS et al (2024) Split intein-mediated protein trans-splicing to express large dystrophins. Nature 632:192\u2013200. https:\/\/doi.org\/10.1038\/s41586-024-07710-8","journal-title":"Nature"},{"key":"5904_CR70","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1038\/s41467-024-50569-6","volume":"15","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhang C, Xiao W et al (2024) Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice. Nat Commun 15:6141. https:\/\/doi.org\/10.1038\/s41467-024-50569-6","journal-title":"Nat Commun"},{"key":"5904_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI189075","author":"H Tasfaout","year":"2025","unstructured":"Tasfaout H, McMillen TS, Reyes TR et al (2025) Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI189075","journal-title":"J Clin Invest"},{"key":"5904_CR72","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1172\/JCI40373","volume":"120","author":"FS Tedesco","year":"2010","unstructured":"Tedesco FS, Dellavalle A, Diaz-Manera J et al (2010) Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 120:11\u201319. https:\/\/doi.org\/10.1172\/JCI40373","journal-title":"J Clin Invest"},{"key":"5904_CR73","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1242\/dev.069088","volume":"139","author":"F Relaix","year":"2012","unstructured":"Relaix F, Zammit PS (2012) Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development 139:2845\u20132856. https:\/\/doi.org\/10.1242\/dev.069088","journal-title":"Development"},{"key":"5904_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S et al (2021) Duchenne muscular dystrophy. Nat Rev Dis Primers 7:1\u201319. https:\/\/doi.org\/10.1038\/s41572-021-00248-3","journal-title":"Nat Rev Dis Primers"},{"key":"5904_CR75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2008.05.049","volume":"134","author":"M Cerletti","year":"2008","unstructured":"Cerletti M, Jurga S, Witczak CA et al (2008) Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 134:37\u201347. https:\/\/doi.org\/10.1016\/j.cell.2008.05.049","journal-title":"Cell"},{"key":"5904_CR76","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1172\/JCI63992","volume":"124","author":"A Marg","year":"2014","unstructured":"Marg A, Escobar H, Gloy S et al (2014) Human satellite cells have regenerative capacity and are genetically manipulable. J Clin Invest 124:4257\u20134265. https:\/\/doi.org\/10.1172\/JCI63992","journal-title":"J Clin Invest"},{"key":"5904_CR77","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1126\/science.1114758","volume":"309","author":"D Montarras","year":"2005","unstructured":"Montarras D, Morgan J, Collins C et al (2005) Direct isolation of satellite cells for skeletal muscle regeneration. Science 309:2064\u20132067. https:\/\/doi.org\/10.1126\/science.1114758","journal-title":"Science"},{"key":"5904_CR78","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nature07384","volume":"456","author":"A Sacco","year":"2008","unstructured":"Sacco A, Doyonnas R, Kraft P et al (2008) Self-renewal and expansion of single transplanted muscle stem cells. Nature 456:502\u2013506. https:\/\/doi.org\/10.1038\/nature07384","journal-title":"Nature"},{"key":"5904_CR79","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2009.01.016","volume":"4","author":"KK Tanaka","year":"2009","unstructured":"Tanaka KK, Hall JK, Troy AA et al (2009) Syndecan-4-expressing muscle progenitor cells in the SP engraft as satellite cells during muscle regeneration. Cell Stem Cell 4:217\u2013225. https:\/\/doi.org\/10.1016\/j.stem.2009.01.016","journal-title":"Cell Stem Cell"},{"key":"5904_CR80","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.stemcr.2015.07.016","volume":"5","author":"X Xu","year":"2015","unstructured":"Xu X, Wilschut KJ, Kouklis G et al (2015) Human satellite cell transplantation and regeneration from diverse skeletal muscles. Stem Cell Rep 5:419\u2013434. https:\/\/doi.org\/10.1016\/j.stemcr.2015.07.016","journal-title":"Stem Cell Rep"},{"key":"5904_CR81","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/mt.2009.167","volume":"17","author":"E Negroni","year":"2009","unstructured":"Negroni E, Riederer I, Chaouch S et al (2009) In vivo myogenic potential of human CD133\u2009+\u2009muscle-derived stem cells: a quantitative study. Mol Ther 17:1771\u20131778. https:\/\/doi.org\/10.1038\/mt.2009.167","journal-title":"Mol Ther"},{"key":"5904_CR82","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.1191035","volume":"329","author":"PM Gilbert","year":"2010","unstructured":"Gilbert PM, Havenstrite KL, Magnusson KEG et al (2010) Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 329:1078\u20131081. https:\/\/doi.org\/10.1126\/science.1191035","journal-title":"Science"},{"key":"5904_CR83","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/273306a0","volume":"273","author":"TA Partridge","year":"1978","unstructured":"Partridge TA, Grounds M, Sloper JC (1978) Evidence of fusion between host and donor myoblasts in skeletal muscle grafts. Nature 273:306\u2013308. https:\/\/doi.org\/10.1038\/273306a0","journal-title":"Nature"},{"key":"5904_CR84","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/337176a0","volume":"337","author":"TA Partridge","year":"1989","unstructured":"Partridge TA, Morgan JE, Coulton GR et al (1989) Conversion of Mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337:176\u2013179. https:\/\/doi.org\/10.1038\/337176a0","journal-title":"Nature"},{"key":"5904_CR85","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/mus.880140302","volume":"14","author":"TA Partridge","year":"1991","unstructured":"Partridge TA (1991) Invited review: myoblast transfer: a possible therapy for inherited myopathies? Muscle Nerve 14:197\u2013212. https:\/\/doi.org\/10.1002\/mus.880140302","journal-title":"Muscle Nerve"},{"key":"5904_CR86","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1442-200x.1991.tb01545.x","volume":"33","author":"PK Law","year":"1991","unstructured":"Law PK, Goodwin TG, Fang QW et al (1991) Myoblast transfer therapy for Duchenne muscular dystrophy. Acta Paediatr Jpn 33:206\u2013215. https:\/\/doi.org\/10.1111\/j.1442-200x.1991.tb01545.x","journal-title":"Acta Paediatr Jpn"},{"key":"5904_CR87","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/0963689792001002-305","volume":"1","author":"PK Law","year":"1992","unstructured":"Law PK, Goodwin TG, Fang Q et al (1992) Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys. Cell Transplant 1:235\u2013244. https:\/\/doi.org\/10.1177\/0963689792001002-305","journal-title":"Cell Transplant"},{"key":"5904_CR88","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/096368979300200607","volume":"2","author":"PK Law","year":"1993","unstructured":"Law PK, Goodwin TG, Fang Q et al (1993) Cell transplantation as an experimental treatment for Duchenne muscular dystrophy. Cell Transplant 2:485\u2013505. https:\/\/doi.org\/10.1177\/096368979300200607","journal-title":"Cell Transplant"},{"key":"5904_CR89","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/nm0997-970","volume":"3","author":"E Gussoni","year":"1997","unstructured":"Gussoni E, Blau HM, Kunkel LM (1997) The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 3:970\u2013977. https:\/\/doi.org\/10.1038\/nm0997-970","journal-title":"Nat Med"},{"key":"5904_CR90","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1056\/NEJM199509283331303","volume":"333","author":"JR Mendell","year":"1995","unstructured":"Mendell JR, Kissel JT, Amato AA et al (1995) Myoblast transfer in the treatment of Duchenne\u2019s muscular dystrophy. N Engl J Med 333:832\u2013838. https:\/\/doi.org\/10.1056\/NEJM199509283331303","journal-title":"N Engl J Med"},{"key":"5904_CR91","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0960-8966(94)00070-p","volume":"5","author":"L Morandi","year":"1995","unstructured":"Morandi L, Bernasconi P, Gebbia M et al (1995) Lack of mRNA and dystrophin expression in DMD patients three months after myoblast transfer. Neuromuscul Disord 5:291\u2013295. https:\/\/doi.org\/10.1016\/0960-8966(94)00070-p","journal-title":"Neuromuscul Disord"},{"key":"5904_CR92","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/scd.2008.0253","volume":"18","author":"UM Fischer","year":"2009","unstructured":"Fischer UM, Harting MT, Jimenez F et al (2009) Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 18:683\u2013692. https:\/\/doi.org\/10.1089\/scd.2008.0253","journal-title":"Stem Cells Dev"},{"key":"5904_CR93","doi-asserted-by":"publisher","unstructured":"Skuk D, Tremblay JP (2014) First study of intra-arterial delivery of myogenic mononuclear cells to skeletal muscles in primates. Cell Transpl 23 Suppl 1:S141-150. https:\/\/doi.org\/10.3727\/096368914X685032","DOI":"10.3727\/096368914X685032"},{"key":"5904_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.859930","volume":"9","author":"C Happi Mbakam","year":"2022","unstructured":"Happi Mbakam C, Lamothe G, Tremblay JP (2022) Therapeutic strategies for dystrophin replacement in Duchenne muscular dystrophy. Front Med Lausanne 9:859930. https:\/\/doi.org\/10.3389\/fmed.2022.859930","journal-title":"Front Med Lausanne"},{"key":"5904_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1190524","author":"KK Saleh","year":"2023","unstructured":"Saleh KK, Switzler C, Hicks MR et al (2023) Duchenne muscular dystrophy disease severity impacts skeletal muscle progenitor cells systemic delivery. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2023.1190524","journal-title":"Front Physiol"},{"key":"5904_CR96","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ncb1542","volume":"9","author":"A Dellavalle","year":"2007","unstructured":"Dellavalle A, Sampaolesi M, Tonlorenzi R et al (2007) Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 9:255\u2013267. https:\/\/doi.org\/10.1038\/ncb1542","journal-title":"Nat Cell Biol"},{"key":"5904_CR97","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nature05282","volume":"444","author":"M Sampaolesi","year":"2006","unstructured":"Sampaolesi M, Blot S, D\u2019Antona G et al (2006) Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444:574\u2013579. https:\/\/doi.org\/10.1038\/nature05282","journal-title":"Nature"},{"key":"5904_CR98","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002342","volume":"3","author":"FS Tedesco","year":"2011","unstructured":"Tedesco FS, Hoshiya H, D\u2019Antona G et al (2011) Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy. Sci Transl Med 3:96ra78. https:\/\/doi.org\/10.1126\/scitranslmed.3002342","journal-title":"Sci Transl Med"},{"key":"5904_CR99","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ymthe.2017.10.013","volume":"26","author":"J Lorant","year":"2018","unstructured":"Lorant J, Saury C, Schleder C et al (2018) Skeletal muscle regenerative potential of human MuStem cells following transplantation into injured mice muscle. Mol Ther 26:618\u2013633. https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.013","journal-title":"Mol Ther"},{"key":"5904_CR100","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.15252\/emmm.201505636","volume":"7","author":"G Cossu","year":"2015","unstructured":"Cossu G, Previtali SC, Napolitano S et al (2015) Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol Med 7:1513\u20131528. https:\/\/doi.org\/10.15252\/emmm.201505636","journal-title":"EMBO Mol Med"},{"key":"5904_CR101","doi-asserted-by":"publisher","first-page":"1056114","DOI":"10.3389\/fgene.2022.1056114","volume":"13","author":"G Cossu","year":"2022","unstructured":"Cossu G, Tonlorenzi R, Brunelli S et al (2022) Mesoangioblasts at 20: from the embryonic aorta to the patient bed. Front Genet 13:1056114. https:\/\/doi.org\/10.3389\/fgene.2022.1056114","journal-title":"Front Genet"},{"key":"5904_CR102","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/j.ajpath.2011.07.022","volume":"179","author":"K Rouger","year":"2011","unstructured":"Rouger K, Larcher T, Dubreil L et al (2011) Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in Duchenne muscular dystrophy dogs. Am J Pathol 179:2501\u20132518. https:\/\/doi.org\/10.1016\/j.ajpath.2011.07.022","journal-title":"Am J Pathol"},{"key":"5904_CR103","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1177\/0963689718776306","volume":"27","author":"J Lorant","year":"2018","unstructured":"Lorant J, Larcher T, Jaulin N et al (2018) Vascular delivery of allogeneic MuStem cells in dystrophic dogs requires only short-term immunosuppression to avoid host immunity and generate clinical\/tissue benefits. Cell Transplant 27:1096\u20131110. https:\/\/doi.org\/10.1177\/0963689718776306","journal-title":"Cell Transplant"},{"key":"5904_CR104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13287-021-02681-3","volume":"13","author":"M Charrier","year":"2022","unstructured":"Charrier M, Lorant J, Contreras-Lopez R et al (2022) Human MuStem cells repress T-cell proliferation and cytotoxicity through both paracrine and contact-dependent pathways. Stem Cell Res Ther 13:7. https:\/\/doi.org\/10.1186\/s13287-021-02681-3","journal-title":"Stem Cell Res Ther"},{"key":"5904_CR105","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jnen\/nlae044","volume":"83","author":"M Charrier","year":"2024","unstructured":"Charrier M, Leroux I, Pichon J et al (2024) Human MuStem cells are competent to fuse with nonhuman primate myofibers in a clinically relevant transplantation context: a proof-of-concept study. J Neuropathol Exp Neurol 83:684\u2013694. https:\/\/doi.org\/10.1093\/jnen\/nlae044","journal-title":"J Neuropathol Exp Neurol"},{"key":"5904_CR106","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nm1705","volume":"14","author":"R Darabi","year":"2008","unstructured":"Darabi R, Gehlbach K, Bachoo RM et al (2008) Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat Med 14:134\u2013143. https:\/\/doi.org\/10.1038\/nm1705","journal-title":"Nat Med"},{"key":"5904_CR107","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1073\/pnas.1808303116","volume":"116","author":"T Incitti","year":"2019","unstructured":"Incitti T, Magli A, Darabi R et al (2019) Pluripotent stem cell-derived myogenic progenitors remodel their molecular signature upon in vivo engraftment. Proc Natl Acad Sci U S A 116:4346\u20134351. https:\/\/doi.org\/10.1073\/pnas.1808303116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5904_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.07.007","author":"K Azzag","year":"2025","unstructured":"Azzag K, Magli A, Kiley J et al (2025) Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies. Mol Ther S. https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.007. 1525-0016(25)00543-X","journal-title":"Mol Ther S"},{"key":"5904_CR109","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.stemcr.2014.07.001","volume":"3","author":"M Shelton","year":"2014","unstructured":"Shelton M, Metz J, Liu J et al (2014) Derivation and expansion of PAX7-positive muscle progenitors from human and mouse embryonic stem cells. Stem Cell Reports 3:516\u2013529. https:\/\/doi.org\/10.1016\/j.stemcr.2014.07.001","journal-title":"Stem Cell Reports"},{"key":"5904_CR110","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.stem.2022.03.004","volume":"29","author":"C Sun","year":"2022","unstructured":"Sun C, Kannan S, Choi IY et al (2022) Human pluripotent stem cell-derived myogenic progenitors undergo maturation to quiescent satellite cells upon engraftment. Cell Stem Cell 29:610\u2013619e5. https:\/\/doi.org\/10.1016\/j.stem.2022.03.004","journal-title":"Cell Stem Cell"},{"key":"5904_CR111","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/ncomms2550","volume":"4","author":"A Filareto","year":"2013","unstructured":"Filareto A, Parker S, Darabi R et al (2013) An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat Commun 4:1549. https:\/\/doi.org\/10.1038\/ncomms2550","journal-title":"Nat Commun"},{"key":"5904_CR112","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.bbrc.2019.09.095","volume":"520","author":"M Sato","year":"2019","unstructured":"Sato M, Shiba N, Miyazaki D et al (2019) Amelioration of intracellular Ca2\u2009+\u2009regulation by exon-45 skipping in Duchenne muscular dystrophy-induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 520:179\u2013185. https:\/\/doi.org\/10.1016\/j.bbrc.2019.09.095","journal-title":"Biochem Biophys Res Commun"},{"key":"5904_CR113","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.stemcr.2020.06.004","volume":"15","author":"M Zhao","year":"2020","unstructured":"Zhao M, Tazumi A, Takayama S et al (2020) Induced fetal human muscle stem cells with high therapeutic potential in a mouse muscular dystrophy model. Stem Cell Reports 15:80\u201394. https:\/\/doi.org\/10.1016\/j.stemcr.2020.06.004","journal-title":"Stem Cell Reports"},{"key":"5904_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102019","volume":"6","author":"A Kowala","year":"2025","unstructured":"Kowala A, Boot J, Meng J et al (2025) Engineered human myogenic cells in hydrogels generate innervated vascularized myofibers within dystrophic mouse muscle on long-term engraftment. Cell Rep Med 6:102019. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102019","journal-title":"Cell Rep Med"},{"key":"5904_CR115","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.stem.2018.06.010","volume":"23","author":"SS-K Chan","year":"2018","unstructured":"Chan SS-K, Arpke RW, Filareto A et al (2018) Skeletal muscle stem cells from PSC-Derived teratomas have functional regenerative capacity. Cell Stem Cell 23:74\u201385e6. https:\/\/doi.org\/10.1016\/j.stem.2018.06.010","journal-title":"Cell Stem Cell"},{"key":"5904_CR116","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.stemcr.2021.10.014","volume":"16","author":"N Xie","year":"2021","unstructured":"Xie N, Chu SN, Azzag K et al (2021) In vitro expanded skeletal myogenic progenitors from pluripotent stem cell-derived teratomas have high engraftment capacity. Stem Cell Reports 16:2900\u20132912. https:\/\/doi.org\/10.1016\/j.stemcr.2021.10.014","journal-title":"Stem Cell Reports"},{"key":"5904_CR117","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.celrep.2018.10.067","volume":"25","author":"J Wu","year":"2018","unstructured":"Wu J, Matthias N, Lo J et al (2018) A myogenic Double-Reporter human pluripotent stem cell line allows prospective isolation of skeletal muscle progenitors. Cell Rep 25:1966\u20131981e4. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.067","journal-title":"Cell Rep"},{"key":"5904_CR118","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.stemcr.2021.03.004","volume":"16","author":"M Nalbandian","year":"2021","unstructured":"Nalbandian M, Zhao M, Sasaki-Honda M et al (2021) Characterization of hiPSC-derived muscle progenitors reveals distinctive markers for myogenic cell purification toward cell therapy. Stem Cell Reports 16:883\u2013898. https:\/\/doi.org\/10.1016\/j.stemcr.2021.03.004","journal-title":"Stem Cell Reports"},{"key":"5904_CR119","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3390\/cells13110972","volume":"13","author":"NR Dhoke","year":"2024","unstructured":"Dhoke NR, Kim H, Azzag K et al (2024) A novel CRISPR-Cas9 strategy to target DYSTROPHIN mutations downstream of exon 44 in patient-specific DMD iPSCs. Cells 13:972. https:\/\/doi.org\/10.3390\/cells13110972","journal-title":"Cells"},{"key":"5904_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-024-00360-4","volume":"9","author":"SB Crist","year":"2024","unstructured":"Crist SB, Azzag K, Kiley J et al (2024) The adult environment promotes the transcriptional maturation of human iPSC-derived muscle grafts. NPJ Regen Med 9:16. https:\/\/doi.org\/10.1038\/s41536-024-00360-4","journal-title":"NPJ Regen Med"},{"key":"5904_CR121","unstructured":"FDA Clears Investigational New Drug application for muscular dystrophy treatment from University of Minnesota startup Myogenica - BioSpace https:\/\/www.biospace.com\/fda-clears-investigational-new-drug-application-for-muscular-dystrophy-treatment-from-university-of-minnesota-startup-myogenica. Accessed 25 Apr 2025"},{"key":"5904_CR122","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/cells12030362","volume":"12","author":"N Xie","year":"2023","unstructured":"Xie N, Chu SN, Schultz CB, Chan SSK (2023) Efficient muscle regeneration by human PSC-derived CD82\u2009+\u2009ERBB3\u2009+\u2009NGFR\u2009+\u2009skeletal myogenic progenitors. Cells 12:362. https:\/\/doi.org\/10.3390\/cells12030362","journal-title":"Cells"},{"key":"5904_CR123","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.stem.2016.08.006","volume":"19","author":"MS Alexander","year":"2016","unstructured":"Alexander MS, Rozkalne A, Colletta A et al (2016) CD82 is a marker for prospective isolation of human muscle satellite cells and is linked to muscular dystrophies. Cell Stem Cell 19:800\u2013807. https:\/\/doi.org\/10.1016\/j.stem.2016.08.006","journal-title":"Cell Stem Cell"},{"key":"5904_CR124","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.stemcr.2023.11.002","volume":"19","author":"R Bou Akar","year":"2024","unstructured":"Bou Akar R, Lama C, Aubin D et al (2024) Generation of highly pure pluripotent stem cell-derived myogenic progenitor cells and myotubes. Stem Cell Reports 19:84\u201399. https:\/\/doi.org\/10.1016\/j.stemcr.2023.11.002","journal-title":"Stem Cell Reports"},{"key":"5904_CR125","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022110655","volume":"41","author":"O Mashinchian","year":"2022","unstructured":"Mashinchian O, De Franceschi F, Nassiri S et al (2022) An engineered multicellular stem cell niche for the 3d derivation of human myogenic progenitors from iPSCs. EMBO J 41:e110655. https:\/\/doi.org\/10.15252\/embj.2022110655","journal-title":"EMBO J"},{"key":"5904_CR126","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s43440-023-00475-3","volume":"75","author":"U G\u0142owniak-Kwitek","year":"2023","unstructured":"G\u0142owniak-Kwitek U, Caballero AL, Bronisz-Budzy\u0144ska I et al (2023) Effect of heme oxygenase-1 on the differentiation of human myoblasts and the regeneration of murine skeletal muscles after acute and chronic injury. Pharmacol Rep 75:397\u2013410. https:\/\/doi.org\/10.1007\/s43440-023-00475-3","journal-title":"Pharmacol Rep"},{"key":"5904_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.702547","volume":"12","author":"O Boyer","year":"2021","unstructured":"Boyer O, Butler-Browne G, Chinoy H et al (2021) Myogenic cell transplantation in genetic and acquired diseases of skeletal muscle. Front Genet 12:702547. https:\/\/doi.org\/10.3389\/fgene.2021.702547","journal-title":"Front Genet"},{"key":"5904_CR128","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114526","volume":"14","author":"S Choi","year":"2022","unstructured":"Choi S, Ferrari G, Moyle LA et al (2022) Assessing and enhancing migration of human myogenic progenitors using directed iPS cell differentiation and advanced tissue modelling. EMBO Mol Med 14:e14526. https:\/\/doi.org\/10.15252\/emmm.202114526","journal-title":"EMBO Mol Med"},{"key":"5904_CR129","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nm.3028","volume":"19","author":"P Bianco","year":"2013","unstructured":"Bianco P, Cao X, Frenette PS et al (2013) The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 19:35\u201342. https:\/\/doi.org\/10.1038\/nm.3028","journal-title":"Nat Med"},{"key":"5904_CR130","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/ars.2017.7159","volume":"29","author":"A Langrzyk","year":"2018","unstructured":"Langrzyk A, Nowak WN, St\u0119pniewski J et al (2018) Critical view on mesenchymal stromal cells in regenerative medicine. Antioxid Redox Signal 29:169\u2013190. https:\/\/doi.org\/10.1089\/ars.2017.7159","journal-title":"Antioxid Redox Signal"},{"key":"5904_CR131","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag0426","volume":"9","author":"D Sipp","year":"2017","unstructured":"Sipp D, Caulfield T, Kaye J et al (2017) Marketing of unproven stem cell-based interventions: a call to action. Sci Transl Med 9:eaag0426. https:\/\/doi.org\/10.1126\/scitranslmed.aag0426","journal-title":"Sci Transl Med"},{"issue":"9","key":"5904_CR132","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1084\/jem.20042224","volume":"201","author":"A-M Rodriguez","year":"2005","unstructured":"Rodriguez A-M, Pisani D, Dechesne CA et al (2005) Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent Mdx mouse. J Exp Med 201(9):1397\u20131405. https:\/\/doi.org\/10.1084\/jem.20042224","journal-title":"J Exp Med"},{"issue":"7","key":"5904_CR133","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3727\/096368911X","volume":"21","author":"NM Vieira","year":"2012","unstructured":"Vieira NM, Valadares M, Zucconi E et al (2012) Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin. Cell Transplant 21(7):1407\u20131417. https:\/\/doi.org\/10.3727\/096368911X","journal-title":"Cell Transplant"},{"key":"5904_CR134","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.stemcr.2016.05.011","volume":"6","author":"B Sacchetti","year":"2016","unstructured":"Sacchetti B, Funari A, Remoli C et al (2016) No identical mesenchymal stem cells at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. Stem Cell Reports 6:897\u2013913. https:\/\/doi.org\/10.1016\/j.stemcr.2016.05.011","journal-title":"Stem Cell Reports"},{"key":"5904_CR135","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/13543784.2024.2313105","volume":"33","author":"A Tang","year":"2024","unstructured":"Tang A, Yokota T (2024) Duchenne muscular dystrophy: promising early-stage clinical trials to watch. Expert Opin Investig Drugs 33:201\u2013217. https:\/\/doi.org\/10.1080\/13543784.2024.2313105","journal-title":"Expert Opin Investig Drugs"},{"key":"5904_CR136","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.stemcr.2023.05.017","volume":"18","author":"J Dulak","year":"2023","unstructured":"Dulak J, Pecyna M (2023) Unproven cell interventions in Poland and the exploitation of European union law on advanced therapy medicinal products. Stem Cell Rep 18:1610\u20131620. https:\/\/doi.org\/10.1016\/j.stemcr.2023.05.017","journal-title":"Stem Cell Rep"},{"key":"5904_CR137","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/d41586-018-06756-9","volume":"561","author":"D Sipp","year":"2018","unstructured":"Sipp D, Robey PG, Turner L (2018) Clear up this stem-cell mess. Nature 561:455\u2013457. https:\/\/doi.org\/10.1038\/d41586-018-06756-9","journal-title":"Nature"},{"key":"5904_CR138","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41556-019-0344-z","volume":"21","author":"M De Luca","year":"2019","unstructured":"De Luca M, Aiuti A, Cossu G et al (2019) Advances in stem cell research and therapeutic development. Nat Cell Biol 21:801\u2013811. https:\/\/doi.org\/10.1038\/s41556-019-0344-z","journal-title":"Nat Cell Biol"},{"key":"5904_CR139","unstructured":"Aartsma-Rus A (2023) Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up \u2022 World Duchenne https:\/\/www.worldduchenne.org\/news\/apaperaday-dystrophin-expressing-chimeric-dec-cell-therapy-for-duchenne-muscular-dystrophy-a-first-in-human-study-with-minimum-6-months-follow-up\/. In: World Duchene.https:\/\/www.worldduchenne.org\/news\/apaperaday-dystrophin-expressing-chimeric-dec-cell-therapy-for-duchenne-muscular-dystrophy-a-first-in-human-study-with-minimum-6-months-follow-up\/Accessed 20 Jan 2025"},{"key":"5904_CR140","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s12015-023-10530-4","volume":"19","author":"A Heydemann","year":"2023","unstructured":"Heydemann A, Bieganski G, Wachowiak J et al (2023) Dystrophin expressing chimeric (DEC) cell therapy for Duchenne muscular dystrophy: a first-in-human study with minimum 6 months follow-up. Stem Cell Rev Rep 19:1340\u20131359. https:\/\/doi.org\/10.1007\/s12015-023-10530-4","journal-title":"Stem Cell Rev Rep"},{"key":"5904_CR141","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12015-018-9807-z","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow M, Cwykiel J, Heydemann A et al (2018) Dystrophin expressing chimeric (DEC) human cells provide a potential therapy for Duchenne muscular dystrophy. Stem Cell Rev Rep 14:370\u2013384. https:\/\/doi.org\/10.1007\/s12015-018-9807-z","journal-title":"Stem Cell Rev Rep"},{"key":"5904_CR142","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s12015-019-09916-0","volume":"15","author":"M Siemionow","year":"2019","unstructured":"Siemionow M, Malik M, Langa P et al (2019) Cardiac protection after systemic transplant of dystrophin expressing chimeric (DEC) cells to the Mdx mouse model of Duchenne muscular dystrophy. Stem Cell Rev Rep 15:827\u2013841. https:\/\/doi.org\/10.1007\/s12015-019-09916-0","journal-title":"Stem Cell Rev Rep"},{"key":"5904_CR143","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/cdd.2008.75","volume":"15","author":"BG Galvez","year":"2008","unstructured":"Galvez BG, Sampaolesi M, Barbuti A et al (2008) Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. Cell Death Differ 15:1417\u20131428. https:\/\/doi.org\/10.1038\/cdd.2008.75","journal-title":"Cell Death Differ"},{"key":"5904_CR144","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5966\/sctm.2012-0107","volume":"2","author":"JL Chun","year":"2013","unstructured":"Chun JL, O\u2019Brien R, Song MH et al (2013) Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in Mdx\/utrn-\/- but not aged Mdx mouse models for Duchenne muscular dystrophy. Stem Cells Transl Med 2:68\u201380. https:\/\/doi.org\/10.5966\/sctm.2012-0107","journal-title":"Stem Cells Transl Med"},{"key":"5904_CR145","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.stemcr.2018.01.023","volume":"10","author":"MA Aminzadeh","year":"2018","unstructured":"Aminzadeh MA, Rogers RG, Fournier M et al (2018) Exosome-mediated benefits of cell therapy in mouse and human models of Duchenne muscular dystrophy. Stem Cell Reports 10:942\u2013955. https:\/\/doi.org\/10.1016\/j.stemcr.2018.01.023","journal-title":"Stem Cell Reports"},{"key":"5904_CR146","doi-asserted-by":"publisher","first-page":"e125754","DOI":"10.1172\/jci.insight.125754","volume":"4","author":"RG Rogers","year":"2019","unstructured":"Rogers RG, Fournier M, Sanchez L et al (2019) Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in Mdx mice. JCI Insight 4:e125754. https:\/\/doi.org\/10.1172\/jci.insight.125754","journal-title":"JCI Insight"},{"key":"5904_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102468","volume":"20","author":"RG Rogers","year":"2025","unstructured":"Rogers RG, Antich J, Fournier M et al (2025) Long-term preservation of muscle function and structure by repeated administration of cardiosphere-derived cells in Mdx mice. Stem Cell Reports 20:102468. https:\/\/doi.org\/10.1016\/j.stemcr.2025.102468","journal-title":"Stem Cell Reports"},{"key":"5904_CR148","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1212\/WNL.0000000000006950","volume":"92","author":"M Taylor","year":"2019","unstructured":"Taylor M, Jefferies J, Byrne B et al (2019) Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology 92:e866\u2013e878. https:\/\/doi.org\/10.1212\/WNL.0000000000006950","journal-title":"Neurology"},{"key":"5904_CR149","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(22)00012-5","volume":"399","author":"CM McDonald","year":"2022","unstructured":"McDonald CM, Marb\u00e1n E, Hendrix S et al (2022) Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 399:1049\u20131058. https:\/\/doi.org\/10.1016\/S0140-6736(22)00012-5","journal-title":"Lancet"},{"key":"5904_CR150","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S0140-6736(22)00185-4","volume":"399","author":"DR Davis","year":"2022","unstructured":"Davis DR (2022) Cell therapy for patients with Duchenne muscular dystrophy. Lancet 399:1024\u20131025. https:\/\/doi.org\/10.1016\/S0140-6736(22)00185-4","journal-title":"Lancet"},{"key":"5904_CR151","unstructured":"Capricor T (2024) Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress. In: Capricor Therapeutics, Inc. https:\/\/www.capricor.com\/investors\/news-events\/press-releases\/detail\/294\/capricor-therapeutics-announces-positive-long-term-data. Accessed 6 Mar 2025"},{"key":"5904_CR152","unstructured":"Manalac T (2025) Capricor Plunges on FDA Rejection of DMD Cell Therapy. In: BioSpace. https:\/\/www.biospace.com\/fda\/capricor-plunges-on-fda-rejection-of-dmd-cell-therapy. Accessed 21 Aug 2025"},{"key":"5904_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08463-0","author":"A-F Jebran","year":"2025","unstructured":"Jebran A-F, Seidler T, Tiburcy M et al (2025) Engineered heart muscle allografts for heart repair in primates and humans. Nature. https:\/\/doi.org\/10.1038\/s41586-024-08463-0","journal-title":"Nature"},{"key":"5904_CR154","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41569-019-0331-x","volume":"17","author":"E Karbassi","year":"2020","unstructured":"Karbassi E, Fenix A, Marchiano S et al (2020) Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat Rev Cardiol 17:341\u2013359. https:\/\/doi.org\/10.1038\/s41569-019-0331-x","journal-title":"Nat Rev Cardiol"},{"key":"5904_CR155","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41587-019-0042-1","volume":"37","author":"KR Chien","year":"2019","unstructured":"Chien KR, Fris\u00e9n J, Fritsche-Danielson R et al (2019) Regenerating the field of cardiovascular cell therapy. Nat Biotechnol 37:232\u2013237. https:\/\/doi.org\/10.1038\/s41587-019-0042-1","journal-title":"Nat Biotechnol"},{"key":"5904_CR156","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.aaz3650","volume":"367","author":"CE Murry","year":"2020","unstructured":"Murry CE, MacLellan WR (2020) Stem cells and the heart-the road ahead. Science 367:854\u2013855. https:\/\/doi.org\/10.1126\/science.aaz3650","journal-title":"Science"},{"key":"5904_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.07.009","author":"J Dulak","year":"2025","unstructured":"Dulak J, Zieli\u0144ski T, J\u00f3zkowicz A, \u0141oboda A (2025) Pluripotent stem cell-based approaches for heart repair and the potential of genetic modifications. Mol Ther S. https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.009. 1525-0016(25)00545\u20133","journal-title":"Mol Ther S"},{"key":"5904_CR158","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00018-022-04434-8","volume":"79","author":"H Kim","year":"2022","unstructured":"Kim H, Perlingeiro RCR (2022) Generation of human myogenic progenitors from pluripotent stem cells for in vivo regeneration. Cell Mol Life Sci 79:406. https:\/\/doi.org\/10.1007\/s00018-022-04434-8","journal-title":"Cell Mol Life Sci"},{"key":"5904_CR159","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00018-024-05229-9","volume":"81","author":"AA Zambon","year":"2024","unstructured":"Zambon AA, Falzone YM, Bolino A, Previtali SC (2024) Molecular mechanisms and therapeutic strategies for neuromuscular diseases. Cell Mol Life Sci 81:198. https:\/\/doi.org\/10.1007\/s00018-024-05229-9","journal-title":"Cell Mol Life Sci"},{"key":"5904_CR160","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.ymthe.2019.08.011","volume":"27","author":"S Selvaraj","year":"2019","unstructured":"Selvaraj S, Dhoke NR, Kiley J et al (2019) Gene correction of LGMD2A patient-specific iPSCs for the development of targeted autologous cell therapy. Mol Ther 27:2147\u20132157. https:\/\/doi.org\/10.1016\/j.ymthe.2019.08.011","journal-title":"Mol Ther"},{"key":"5904_CR161","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.omtn.2023.02.005","volume":"31","author":"S M\u00fcthel","year":"2023","unstructured":"M\u00fcthel S, Marg A, Ignak B et al (2023) Cas9-induced single cut enables highly efficient and template-free repair of a muscular dystrophy causing founder mutation. Mol Ther 31:494\u2013511. https:\/\/doi.org\/10.1016\/j.omtn.2023.02.005","journal-title":"Mol Ther"},{"key":"5904_CR162","unstructured":"Levy J (2024) Vita Therapeutics letter to the LGMD2A\/R1 community. In: Coalition to Cure Calpain 3. https:\/\/www.curecalpain3.org\/vita-therapeutics-letter-to-the-lgmd2a-r1-community\/. Accessed 21 Aug 2025"},{"key":"5904_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-022-00249-0","volume":"7","author":"K Azzag","year":"2022","unstructured":"Azzag K, Bosnakovski D, Tungtur S et al (2022) Transplantation of PSC-derived myogenic progenitors counteracts disease phenotypes in FSHD mice. NPJ Regen Med 7:43. https:\/\/doi.org\/10.1038\/s41536-022-00249-0","journal-title":"NPJ Regen Med"},{"key":"5904_CR164","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/mt.2013.155","volume":"22","author":"S P\u00e9ri\u00e9","year":"2014","unstructured":"P\u00e9ri\u00e9 S, Trollet C, Mouly V et al (2014) Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase i\/iia clinical study. Mol Ther 22:219\u2013225. https:\/\/doi.org\/10.1038\/mt.2013.155","journal-title":"Mol Ther"},{"key":"5904_CR165","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A et al (2022) CAR T cells produced in vivo to treat cardiac injury. Science 375:91\u201396. https:\/\/doi.org\/10.1126\/science.abm0594","journal-title":"Science"},{"key":"5904_CR166","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG et al (2019) Targeting cardiac fibrosis with engineered T cells. Nature 573:430\u2013433. https:\/\/doi.org\/10.1038\/s41586-019-1546-z","journal-title":"Nature"},{"key":"5904_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114061","volume":"158","author":"G Ferrer-Curriu","year":"2023","unstructured":"Ferrer-Curriu G, Soler-Botija C, Charvatova S et al (2023) Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy. Biomed Pharmacother 158:114061. https:\/\/doi.org\/10.1016\/j.biopha.2022.114061","journal-title":"Biomed Pharmacother"},{"key":"5904_CR168","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s13346-023-01308-9","volume":"13","author":"S Shahvali","year":"2023","unstructured":"Shahvali S, Rahiman N, Jaafari MR, Arabi L (2023) Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv Transl Res 13:2041\u20132056. https:\/\/doi.org\/10.1007\/s13346-023-01308-9","journal-title":"Drug Deliv Transl Res"},{"key":"5904_CR169","doi-asserted-by":"publisher","first-page":"A13851","DOI":"10.1161\/circ.148.suppl_1.13851","volume":"148","author":"C Marigny","year":"2023","unstructured":"Marigny C, Revet G, Berger A et al (2023) Abstract 13851: CAR-T cells: a potential novel strategy for mitigating fibrosis in Duchenne muscular dystrophy. Circulation 148:A13851\u2013A13851. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.13851","journal-title":"Circulation"},{"key":"5904_CR170","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1212\/WNL.0000000000000498","volume":"82","author":"MD Nelson","year":"2014","unstructured":"Nelson MD, Rader F, Tang X et al (2014) Pde5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 82:2085\u20132091. https:\/\/doi.org\/10.1212\/WNL.0000000000000498","journal-title":"Neurology"},{"key":"5904_CR171","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1089\/ars.2012.4604","volume":"19","author":"SI Dikalov","year":"2013","unstructured":"Dikalov SI, Nazarewicz RR (2013) Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxid Redox Signal 19:1085\u20131094. https:\/\/doi.org\/10.1089\/ars.2012.4604","journal-title":"Antioxid Redox Signal"},{"key":"5904_CR172","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.jacc.2016.02.081","volume":"67","author":"F Kamdar","year":"2016","unstructured":"Kamdar F, Garry DJ (2016) Dystrophin-deficient cardiomyopathy. J Am Coll Cardiol 67:2533\u20132546. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.081","journal-title":"J Am Coll Cardiol"},{"key":"5904_CR173","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ahj.2007.05.014","volume":"154","author":"D Duboc","year":"2007","unstructured":"Duboc D, Meune C, Pierre B et al (2007) Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years\u2019 follow-up. Am Heart J 154:596\u2013602. https:\/\/doi.org\/10.1016\/j.ahj.2007.05.014","journal-title":"Am Heart J"},{"key":"5904_CR174","doi-asserted-by":"publisher","DOI":"10.1371\/currents.md.2cc69a1dae4be7dfe2bcb420024ea865","author":"HD Allen","year":"2013","unstructured":"Allen HD, Flanigan KM, Thrush PT et al (2013) A randomized, double-blind trial of Lisinopril and Losartan for the treatment of cardiomyopathy in Duchenne muscular dystrophy. PLoS Curr 5:ecurrents.md.2cc69a1dae4be7dfe2bcb420024ea865 https:\/\/doi.org\/10.1371\/currents.md.2cc69a1dae4be7dfe2bcb420024ea865","journal-title":"PLoS Curr 5:ecurrents Md"},{"key":"5904_CR175","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","volume":"91","author":"S Bangalore","year":"2016","unstructured":"Bangalore S, Fakheri R, Toklu B et al (2016) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure?? Insights from 254,301 patients from randomized trials. Mayo Clin Proc 91:51\u201360. https:\/\/doi.org\/10.1016\/j.mayocp.2015.10.019","journal-title":"Mayo Clin Proc"},{"key":"5904_CR176","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1253\/circj.70.991","volume":"70","author":"H Kajimoto","year":"2006","unstructured":"Kajimoto H, Ishigaki K, Okumura K et al (2006) Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 70:991\u2013994. https:\/\/doi.org\/10.1253\/circj.70.991","journal-title":"Circ J"},{"key":"5904_CR177","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2012.02.064","volume":"110","author":"L Viollet","year":"2012","unstructured":"Viollet L, Thrush PT, Flanigan KM et al (2012) Effects of angiotensin-converting enzyme inhibitors and\/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 110:98\u2013102. https:\/\/doi.org\/10.1016\/j.amjcard.2012.02.064","journal-title":"Am J Cardiol"},{"key":"5904_CR178","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022572","author":"JP Bourke","year":"2018","unstructured":"Bourke JP, Watson G, Muntoni F et al (2018) Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD heart protection study): a protocol study. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2018-022572","journal-title":"BMJ Open"},{"key":"5904_CR179","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/S0735-1097(17)34259-6","volume":"69","author":"M Ploutz","year":"2017","unstructured":"Ploutz M, Moore R, Ashiki M et al (2017) Spironolactone therapy for cardiomyopathy in Duchenne muscular dystrophy. J Am Coll Cardiol 69:870\u2013870. https:\/\/doi.org\/10.1016\/S0735-1097(17)34259-6","journal-title":"J Am Coll Cardiol"},{"key":"5904_CR180","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","volume":"14","author":"SV Raman","year":"2015","unstructured":"Raman SV, Hor KN, Mazur W et al (2015) Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 14:153\u2013161. https:\/\/doi.org\/10.1016\/S1474-4422(14)70318-7","journal-title":"Lancet Neurol"},{"key":"5904_CR181","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13023-017-0590-8","volume":"12","author":"SV Raman","year":"2017","unstructured":"Raman SV, Hor KN, Mazur W et al (2017) Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial. Orphanet J Rare Dis 12:39. https:\/\/doi.org\/10.1186\/s13023-017-0590-8","journal-title":"Orphanet J Rare Dis"},{"key":"5904_CR182","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1021\/jm200135z","volume":"54","author":"DR Chancellor","year":"2011","unstructured":"Chancellor DR, Davies KE, De Moor O et al (2011) Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy. J Med Chem 54:3241\u20133250. https:\/\/doi.org\/10.1021\/jm200135z","journal-title":"J Med Chem"},{"key":"5904_CR183","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/nan.12735","volume":"47","author":"P Soblechero-Mart\u00edn","year":"2021","unstructured":"Soblechero-Mart\u00edn P, L\u00f3pez-Mart\u00ednez A, de la Puente-Ovejero L et al (2021) Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. Neuropathol Appl Neurobiol 47:711\u2013723. https:\/\/doi.org\/10.1111\/nan.12735","journal-title":"Neuropathol Appl Neurobiol"},{"key":"5904_CR184","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.molmed.2024.01.007","volume":"30","author":"C Mozzetta","year":"2024","unstructured":"Mozzetta C, Sartorelli V, Steinkuhler C, Puri PL (2024) HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients. Trends Mol Med 30:278\u2013294. https:\/\/doi.org\/10.1016\/j.molmed.2024.01.007","journal-title":"Trends Mol Med"},{"key":"5904_CR185","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2018342118","volume":"118","author":"RA Ellwood","year":"2021","unstructured":"Ellwood RA, Hewitt JE, Torregrossa R et al (2021) Mitochondrial hydrogen sulfide supplementation improves health in the C. elegans Duchenne muscular dystrophy model. Proc Natl Acad Sci U S A 118:e2018342118. https:\/\/doi.org\/10.1073\/pnas.2018342118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5904_CR186","doi-asserted-by":"publisher","first-page":"102040","DOI":"10.1016\/j.redox.2021.102040","volume":"45","author":"E Panza","year":"2021","unstructured":"Panza E, Vellecco V, Iannotti FA et al (2021) Duchenne\u2019s muscular dystrophy involves a defective transsulfuration pathway activity. Redox Biol 45:102040. https:\/\/doi.org\/10.1016\/j.redox.2021.102040","journal-title":"Redox Biol"},{"key":"5904_CR187","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.258429","volume":"134","author":"M Saclier","year":"2021","unstructured":"Saclier M, Ben Larbi S, My Ly H et al (2021) Interplay between myofibers and pro-inflammatory macrophages controls muscle damage in Mdx mice. J Cell Sci 134:jcs258429. https:\/\/doi.org\/10.1242\/jcs.258429","journal-title":"J Cell Sci"},{"key":"5904_CR188","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/mt.2012.188","volume":"20","author":"S Goudenege","year":"2012","unstructured":"Goudenege S, Lebel C, Huot NB et al (2012) Myoblasts derived from normal hESCs and dystrophic HiPSCs efficiently fuse with existing muscle fibers following transplantation. Mol Ther 20:2153\u20132167. https:\/\/doi.org\/10.1038\/mt.2012.188","journal-title":"Mol Ther"},{"key":"5904_CR189","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.stem.2012.02.015","volume":"10","author":"R Darabi","year":"2012","unstructured":"Darabi R, Arpke RW, Irion S et al (2012) Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 10:610\u2013619. https:\/\/doi.org\/10.1016\/j.stem.2012.02.015","journal-title":"Cell Stem Cell"},{"key":"5904_CR190","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41556-017-0010-2","volume":"20","author":"MR Hicks","year":"2018","unstructured":"Hicks MR, Hiserodt J, Paras K et al (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46\u201357. https:\/\/doi.org\/10.1038\/s41556-017-0010-2","journal-title":"Nat Cell Biol"},{"key":"5904_CR191","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young CS, Hicks MR, Ermolova NV et al (2016) A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18:533\u2013540. https:\/\/doi.org\/10.1016\/j.stem.2016.01.021","journal-title":"Cell Stem Cell"},{"key":"5904_CR192","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.celrep.2016.05.016","volume":"15","author":"IY Choi","year":"2016","unstructured":"Choi IY, Lim H, Estrellas K et al (2016) Concordant but varied phenotypes among Duchenne muscular dystrophy patient-specific myoblasts derived using a human iPSC-based model. Cell Rep 15:2301\u20132312. https:\/\/doi.org\/10.1016\/j.celrep.2016.05.016","journal-title":"Cell Rep"},{"key":"5904_CR193","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1016\/j.celrep.2017.06.005","volume":"19","author":"A Magli","year":"2017","unstructured":"Magli A, Incitti T, Kiley J et al (2017) PAX7 targets, CD54, integrin \u03b19\u03b21, and SDC2, allow isolation of human ESC\/iPSC-derived myogenic progenitors. Cell Rep 19:2867\u20132877. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.005","journal-title":"Cell Rep"},{"key":"5904_CR194","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.stemcr.2020.11.001","volume":"16","author":"H Kim","year":"2021","unstructured":"Kim H, Selvaraj S, Kiley J et al (2021) Genomic safe harbor expression of PAX7 for the generation of engraftable myogenic progenitors. Stem Cell Rep 16:10\u201319. https:\/\/doi.org\/10.1016\/j.stemcr.2020.11.001","journal-title":"Stem Cell Rep"},{"key":"5904_CR195","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1093\/hmg\/ddx252","volume":"26","author":"P Frattini","year":"2017","unstructured":"Frattini P, Villa C, De Santis F et al (2017) Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I. Hum Mol Genet 26:3682\u20133698. https:\/\/doi.org\/10.1093\/hmg\/ddx252","journal-title":"Hum Mol Genet"},{"key":"5904_CR196","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13395-020-00228-3","volume":"10","author":"K Azzag","year":"2020","unstructured":"Azzag K, Ortiz-Cordero C, Oliveira NAJ et al (2020) Efficient engraftment of pluripotent stem cell-derived myogenic progenitors in a novel immunodeficient mouse model of limb girdle muscular dystrophy 2I. Skelet Muscle 10:10. https:\/\/doi.org\/10.1186\/s13395-020-00228-3","journal-title":"Skelet Muscle"},{"key":"5904_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109360","volume":"36","author":"NR Dhoke","year":"2021","unstructured":"Dhoke NR, Kim H, Selvaraj S et al (2021) A universal gene correction approach for FKRP-associated dystroglycanopathies to enable autologous cell therapy. Cell Rep 36:109360. https:\/\/doi.org\/10.1016\/j.celrep.2021.109360","journal-title":"Cell Rep"},{"key":"5904_CR198","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003541","volume":"4","author":"FS Tedesco","year":"2012","unstructured":"Tedesco FS, Gerli MFM, Perani L et al (2012) Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med 4:140ra89. https:\/\/doi.org\/10.1126\/scitranslmed.3003541","journal-title":"Sci Transl Med"},{"key":"5904_CR199","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.omtn.2023.07.037","volume":"33","author":"JL Ortiz-Vitali","year":"2023","unstructured":"Ortiz-Vitali JL, Wu J, Xu N et al (2023) Disease modeling and gene correction of LGMDR21 iPSCs elucidates the role of POGLUT1 in skeletal muscle maintenance, regeneration, and the satellite cell niche. Mol Ther 33:683\u2013697. https:\/\/doi.org\/10.1016\/j.omtn.2023.07.037","journal-title":"Mol Ther"},{"key":"5904_CR200","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41467-024-55086-0","volume":"16","author":"H Escobar","year":"2025","unstructured":"Escobar H, Di Francescantonio S, Smirnova J et al (2025) Gene-editing in patient and humanized-mice primary muscle stem cells rescues dysferlin expression in dysferlin-deficient muscular dystrophy. Nat Commun 16:120. https:\/\/doi.org\/10.1038\/s41467-024-55086-0","journal-title":"Nat Commun"},{"key":"5904_CR201","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/s0960-8966(01)00254-1","volume":"12","author":"K Leriche-Gu\u00e9rin","year":"2002","unstructured":"Leriche-Gu\u00e9rin K, Anderson LVB, Wrogemann K et al (2002) Dysferlin expression after normal myoblast transplantation in SCID and in SJL mice. Neuromuscul Disord 12:167\u2013173. https:\/\/doi.org\/10.1016\/s0960-8966(01)00254-1","journal-title":"Neuromuscul Disord"},{"key":"5904_CR202","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.expneurol.2009.08.002","volume":"220","author":"R Darabi","year":"2009","unstructured":"Darabi R, Baik J, Clee M et al (2009) Engraftment of embryonic stem cell-derived myogenic progenitors in a dominant model of muscular dystrophy. Exp Neurol 220:212\u2013216. https:\/\/doi.org\/10.1016\/j.expneurol.2009.08.002","journal-title":"Exp Neurol"},{"key":"5904_CR203","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.nmd.2018.05.007","volume":"28","author":"V Straub","year":"2018","unstructured":"Straub V, Murphy A, Udd B et al (2018) 229th ENMC international workshop: limb girdle muscular dystrophies \u2013 nomenclature and reformed classification naarden, the netherlands, 17\u201319 march 2017. Neuromuscul Disord 28:702\u2013710. https:\/\/doi.org\/10.1016\/j.nmd.2018.05.007","journal-title":"Neuromuscul Disord"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05904-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:02:07Z","timestamp":1760202127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05904-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":203,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5904"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05904-5","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"356"}}